Joshua Jennings
Stock Analyst at TD Cowen
(3.77)
# 837
Out of 4,413 analysts
41
Total ratings
46.51%
Success rate
9.93%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Maintains: Buy | $365 → $400 | $328.12 | +21.91% | 2 | Apr 11, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $50 → $60 | $50.61 | +18.55% | 3 | Mar 12, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $65 → $77 | $72.21 | +6.63% | 3 | Mar 7, 2024 | |
| TMDX TransMedics Group | Maintains: Outperform | $95 → $110 | $117.60 | -6.46% | 4 | Aug 4, 2023 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $52 → $34 | $36.20 | -6.08% | 2 | Aug 4, 2023 | |
| PROF Profound Medical | Maintains: Outperform | $14 → $18 | $7.45 | +141.61% | 3 | May 11, 2023 | |
| BAX Baxter International | Maintains: Outperform | $70 → $45 | $40.34 | +11.55% | 2 | Feb 10, 2023 | |
| DXCM DexCom | Maintains: Outperform | $114 → $125 | $125.88 | -0.70% | 1 | Feb 10, 2023 | |
| MDWD MediWound | Maintains: Outperform | $6 → $25 | $19.27 | +29.74% | 1 | Dec 30, 2022 | |
| ABT Abbott Laboratories | Maintains: Outperform | $130 | $106.29 | +22.31% | 9 | Dec 13, 2022 | |
| STXS Stereotaxis | Maintains: Outperform | $7 → $5 | $2.41 | +107.47% | 1 | Nov 11, 2022 | |
| OM Outset Medical | Maintains: Outperform | $60 → $33 | $2.85 | +1,057.89% | 2 | Jun 14, 2022 | |
| MDT Medtronic | Maintains: Outperform | $125 → $117 | $80.89 | +44.64% | 2 | May 27, 2022 | |
| RBOT Vicarious Surgical | Initiates: Outperform | n/a | $0.28 | - | 1 | Dec 7, 2021 | |
| HUMA Humacyte | Initiates: Outperform | n/a | $4.40 | - | 1 | Oct 29, 2021 | |
| PRCT PROCEPT BioRobotics | Initiates: Outperform | n/a | $60.61 | - | 1 | Oct 11, 2021 | |
| ATEC Alphatec Holdings | Initiates: Outperform | n/a | $12.97 | - | 1 | Sep 3, 2020 | |
| BDX Becton, Dickinson and Company | Downgrades: Market Perform | n/a | $233.72 | - | 1 | Feb 7, 2020 | |
| VIVE Viveve Medical | Initiates: Outperform | n/a | $0.00 | - | 1 | May 3, 2017 |
Stryker
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $328.12
Upside: +21.91%
Establishment Labs Holdings
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $50.61
Upside: +18.55%
Boston Scientific
Mar 7, 2024
Maintains: Outperform
Price Target: $65 → $77
Current: $72.21
Upside: +6.63%
TransMedics Group
Aug 4, 2023
Maintains: Outperform
Price Target: $95 → $110
Current: $117.60
Upside: -6.46%
Tandem Diabetes Care
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $36.20
Upside: -6.08%
Profound Medical
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $7.45
Upside: +141.61%
Baxter International
Feb 10, 2023
Maintains: Outperform
Price Target: $70 → $45
Current: $40.34
Upside: +11.55%
DexCom
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $125.88
Upside: -0.70%
MediWound
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $19.27
Upside: +29.74%
Abbott Laboratories
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $106.29
Upside: +22.31%
Stereotaxis
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.41
Upside: +107.47%
Outset Medical
Jun 14, 2022
Maintains: Outperform
Price Target: $60 → $33
Current: $2.85
Upside: +1,057.89%
Medtronic
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $80.89
Upside: +44.64%
Vicarious Surgical
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.28
Upside: -
Humacyte
Oct 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.40
Upside: -
PROCEPT BioRobotics
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $60.61
Upside: -
Alphatec Holdings
Sep 3, 2020
Initiates: Outperform
Price Target: n/a
Current: $12.97
Upside: -
Becton, Dickinson and Company
Feb 7, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $233.72
Upside: -
Viveve Medical
May 3, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.00
Upside: -